文献速递冠心病

非ST段抬高型急性冠脉综合征中P2Y12抑制剂预处理:NCDR胸痛-心梗注册研究

P2Y12 Inhibitor Pretreatment in Non-ST-Segment Elevation Acute Coronary Syndrome: The NCDR Chest Pain-MI Registry.
PubMed 文献 · J Am Coll Cardiol · 2024-11-15

基于美国NCDR胸痛-心梗注册研究,分析2013至2023年接受早期侵入策略的NSTE-ACS患者,P2Y12抑制剂预处理比例从24.8%降至12.4%;2019至2023年队列中15.9%接受预处理,不同操作者/机构间使用差异显著,工具变量分析显示预处理与院内全因死亡、再发心梗或大出血无显著差异,但CABG患者住院时间延长。

要点

  • NSTE-ACS患者P2Y12抑制剂预处理使用率呈下降趋势,从2013Q1的24.8%降至2023Q1的12.4%。
  • 不同操作者或机构间预处理使用差异显著,相似患者接受预处理的 odds 中位 OR 分别为3.74和3.63。
  • 工具变量分析未发现预处理与院内死亡、再发心梗或大出血显著相关,但CABG患者住院时间延长。

核心结论

  • 美国NCDR注册研究中,NSTE-ACS患者P2Y12抑制剂预处理使用存在显著操作者/机构间差异。
  • 预处理缺乏明确优势且可能延长CABG患者住院时间,提示需推动标准化。

研究设计与样本

  • 基于美国NCDR胸痛-心梗注册研究,分析接受早期侵入策略(到院24小时内冠脉造影)的NSTE-ACS连续患者。
  • 时间趋势分析覆盖2013年1月1日至2023年3月31日完整队列。
  • 近期队列(2019年1月1日至2023年3月31日)共110,148例,平均年龄63.9±12.5岁,女性33.0%,用于构建分层回归模型和工具变量分析。

主要发现

  • P2Y12抑制剂预处理比例从2013Q1的24.8%降至2023Q1的12.4%。
  • 近期队列中17,509例(15.9%)接受预处理;预处理使用范围0%-100%,分层回归模型显示随机操作者或机构间中位OR分别为3.74(95%CI 3.57-3.91)和3.63(95%CI 3.51-3.74)。
  • 工具变量分析显示预处理与院内全因死亡(1.5% vs 1.7%;P=0.07)、再发心梗(0.6% vs 0.6%;P=0.98)、大出血(2.7% vs 2.8%;P=0.98)无显著差异。
  • 接受冠脉搭桥手术的患者中,预处理与更长住院时间相关(11.2±5.1天 vs 9.8±5.0天;P<0.01)。

临床怎么用

  • NSTE-ACS患者P2Y12抑制剂预处理使用需个体化决策,尤其对于可能需CABG的患者应权衡住院时间延长风险。
  • 应关注并减少操作者/机构间预处理使用的显著差异,推动标准化实践。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Although high rates of P2Y12 inhibitor pretreatment (defined as the administration before coronary angiography) for non-ST-segment elevation acute coronary syndrome (NSTE-ACS) have been reported, contemporary U.S. practice patterns are not well studied. OBJECTIVES: The goal of this study was to investigate the temporal U.S. trends, variability, and clinical outcomes of P2Y12 inhibitor pretreatment in NSTE-ACS. METHODS: Consecutive patients who underwent early invasive strategy for NSTE-ACS (coronary angiography ≤24 hours of arrival) in the National Cardiovascular Data Registry Chest Pain-Myocardial Infarction (MI) Registry were analyzed. A time-trend analysis was conducted on a complete cohort between January 1, 2013, and March 31, 2023. Subsequently, a more recent cohort (January 1, 2019, to March 31, 2023) with a complete set of variables was used to construct hierarchical regression models to quantify the variability in the use of pretreatment among operators and institutions. For this contemporary cohort, instrumental variable analysis, with operator preference as the instrument, was performed to compare the in-hospital outcomes between patients who received pretreatment and those who did not. RESULTS: Use of P2Y12 inhibitor pretreatment decreased from 24.8% in 2013Q1 to 12.4% in 2023Q1. Among the contemporary cohort of 110,148 patients (2019-2023; mean age 63.9 ± 12.5 years; 33.0% female), 17,509 (15.9%) received pretreatment. Significant variability in P2Y12 inhibitor pretreatment was observed (range: 0%-100%): hierarchical regression model demonstrated that 2 similar patients would have a >3-fold difference in the odds of pretreatment from 1 random operator or institution as compared with another (median OR: 3.74 [95% CI: 3.57-3.91] and 3.63 [95% CI: 3.51-3.74], respectively). Instrumental variable analysis demonstrated no significant differences in in-hospital all-cause death (1.5% vs 1.7%; P = 0.07), recurrent MI (0.6% vs 0.6%; P = 0.98), or major bleeding (2.7% vs 2.8%; P = 0.98) with pretreatment. However, in patients who underwent coronary artery bypass surgery, pretreatment was associated with a longer length of stay (11.2 ± 5.1 days vs 9.8 ± 5.0 days; P < 0.01). CONCLUSIONS: In a national U.S. registry, we observed significant variability in the use of P2Y12 inhibitor pretreatment among NSTE-ACS patients. Given the lack of clear advantages and the potential for prolonged hospital stays, our findings highlight the importance of efforts to improve standardization.

来源:J Am Coll Cardiol,查看原文。版权归原作者所有。

引用

  1. Ueyama HA, Kennedy KF, Rymer JA, et al. P2Y12 Inhibitor Pretreatment in Non-ST-Segment Elevation Acute Coronary Syndrome: The NCDR Chest Pain-MI Registry. J Am Coll Cardiol. 2024. PMID: 39545905. doi:10.1016/j.jacc.2024.09.1227

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。